ArticleFrontiers in surgery2026
A retrospective study comparing holmium Laser enucleation vs. transurethral resection for the treatment of benign prostatic hyperplasia.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Benign prostatic hyperplasia (BPH) is a common condition in aging men that significantly impacts quality of life. This study aimed to compare the perioperative outcomes and short-term efficacy of holmium laser enucleation of the prostate (HoLEP) vs. transurethral resection of the prostate (TURP) in patients with symptomatic BPH. Methods: We retrospectively analyzed data from 176 patients who underwent surgical treatment for BPH at our institution between January 2019 and December 2024. Patients were divided into two groups: HoLEP ( Results: Baseline demographics and prostate volume were similar between the two groups. The HoLEP group showed significantly shorter operation time (58.26 ± 20.11 min vs. 84.17 ± 36.80 min, Conclusion: HoLEP is a safe and effective alternative to TURP for BPH, offering advantages in perioperative safety and early recovery. It may be particularly beneficial in patients with large prostates or higher bleeding risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.